Proof of Concept Test on the efficacy of ultrasonography contrast agent perflurubutane in the differential diagnosis of nodular thyroid lesions

Proof of Concept Test on the efficacy of ultrasonography contrast agent perflurubutane in the differential diagnosis of nodular thyroid lesions - Proof of Concept Test on the efficacy of ultrasonography contrast agent perflurubutane in the differential diagnosis of nodular thyroid lesions

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020905

Enrollment

Registered

2016-02-08

Start date

2016-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nodular thyroid lesions(bening and malignant)

Interventions

After non-enhanced ultrasonography, patients will receive a dose of the contrast agent. One vial (16microliter) of perflubutane will be suspected in 2ml of water for intravenous injection. 0.003ml/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with a thyroid nodule depicted on non-enhanced sonography, and have been diagnosed as either benign or malignant on fine needle aspiration cytology 2.Patients 20 years of age or older when giving consent 3.Patients without history of thyroidectomy

Exclusion criteria

Exclusion criteria: 1.Patients with a history of hypersensitivity to contents of perflurubutane 2.Patients who are pregnant,possibly pregnant,or nursing 3 Patients with allergies to eggs or egg products 4.Patients with pulmonary arterovenous shunts in the heart or lungs 5.Patients with severe heart or lung disease 6.Patients receiving drug therapy (such as chemotherapy) or radiotherapy for cancer,or will receive such therapy within two days of receiving contrast 7.Patients considered inappropriate for achieving the purpose this clinical study by the principal investigator or investigator.

Design outcomes

Primary

Measure	Time frame
Contrast enhanced ultrasonography findings (will evaluate contrast enhancement patterns and vascularity patterns)	—

Secondary

Measure	Time frame
1.Evaluating contrast enhancement (will evaluate contrast enhanced sonography using three different ultrasound contrast agents). 2.Non-enhanced ultrasonography findings	—

Countries

Japan

Contacts

Public ContactHiromi Hirasawa

Gunma University Hospital department of nuclear medecine

h.hirasawa@gunma-u.ac.jp027-220-8612

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026